Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Vipadenant
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

DC Chemicals Limited
China
Product Name: Vipadenant
Price: $550.0/100mg $900.0/250mg $1900.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

ShangHai DC Chemicals Co.,Ltd
China
Product Name: Vipadenant
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Lai

442908-10-3

442908-10-3 structure

442908-10-3 structure

Name: Vipadenant
Chemical Name: 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
CAS Number: 442908-10-3
Molecular Formula: C₁₆H₁₅N₇O
Molecular Weight: 321.33700
Catalog: Signaling Pathways GPCR/G Protein Adenosine Receptor
Create Date: 2018-12-23 17:06:55
Modify Date: 2024-01-10 15:36:59
Vipadenant is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively.

Name	3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
Synonyms	VER-ADO-49 VER-A00-11 Vipadenant V-2006 CEB-4520 UNII-LDR3USH1NJ

Description	Vipadenant is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adenosine Receptor Research Areas >> Neurological Disease
Target	Ki: 1.3 nM (A2A), 68 nM (A1)[1], 1005 nM (A3)[2]
In Vivo	Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2].
References	[1]. Jones N, et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013 Sep;98:163-9. [2]. Brian C. Shook, et al. Adenosine A2A Receptor Antagonists and Parkinson’s Disease. ACS Chem Neurosci. 2011 Oct 19; 2(10): 555-567.

Molecular Formula	C₁₆H₁₅N₇O
Molecular Weight	321.33700
Exact Mass	321.13400
PSA	122.40000
LogP	2.51370
Storage condition	2-8℃

442908-07-8 structure

442908-07-8

~91%

442908-10-3 structure

442908-10-3

Literature: BIOGEN IDEC MA INC.; VERNALIS RESEARCH LIMITED Patent: WO2008/86201 A1, 2008 ; Location in patent: Page/Page column 21 ; WO 2008/086201 A1

442906-78-7 structure

442906-78-7

141281-38-1 structure

141281-38-1

~%

442908-10-3 structure

442908-10-3

Literature: Gillespie, Roger J.; Bamford, Samantha J.; Botting, Ruth; Comer, Mike; Denny, Sarah; Gaur, Suneel; Griffin, Michael; Jordan, Allan M.; Knight, Anthony R.; Lerpiniere, Joanne; Leonardi, Stefania; Lightowler, Sean; McAteer, Steven; Merrett, Angela; Misra, Anil; Padfield, Antony; Reece, Mark; Saadi, Mona; Selwood, Daniel L.; Stratton, Gemma C.; Surry, Dominic; Todd, Richard; Tong, Xin; Ruston, Vicki; Upton, Rebecca; Weiss, Scott M. Journal of Medicinal Chemistry, 2009 , vol. 52, # 1 p. 33 - 47

Precursor 2
442908-07-8 141281-38-1
DownStream 0